Advertisement

International Journal of Clinical Pharmacy

, Volume 37, Issue 5, pp 782–789 | Cite as

Medicines taken by older Australians after transient ischaemic attack or ischaemic stroke: a retrospective database study

  • Janet K. SluggettEmail author
  • Gillian E. Caughey
  • Michael B. Ward
  • Andrew L. Gilbert
Research Article

Abstract

Background Guidelines recommend patients diagnosed with transient ischaemic attack (TIA) or ischaemic stroke receive antihypertensive, antithrombotic and lipid lowering medicines. Reassessment of the need for medicines associated with an increased risk of stroke is also recommended. Objective To determine changes in the use of medicines recommended for secondary stroke prevention, medicines commonly used for treating stroke-related complications and medicines not recommended for use after ischaemic stroke, and to determine patient characteristics associated with use of all three stroke prevention medicines after TIA or ischaemic stroke. Setting Administrative health claims data from the Australian Government Department of Veterans’ Affairs. Method This retrospective study included patients with a first-ever hospitalisation for TIA or ischaemic stroke in 2009 and alive at 4 months after discharge. Changes to medicines dispensed in the 4 months before and after hospitalisation were compared using McNemar’s test. Log binomial regression analysis was used to determine patient characteristics associated with use of all three secondary stroke prevention medicines after hospitalisation for TIA or ischaemic stroke. Main outcome measure Prevalence of medicine use after hospitalisation. Results 1541 patients (853 TIA, 688 ischaemic stroke) were included, with a median age of 85 years. High use of antihypertensive (82 % TIA, 86 % ischaemic stroke) and antithrombotic (84 % TIA, 90 % ischaemic stroke) medicines was observed postdischarge, with 58 % of TIA and 73 % of ischaemic stroke patients receiving lipid lowering therapy. Half of the population (47 % TIA, 61 % ischaemic stroke) were dispensed all three classes of medicines recommended for secondary stroke prevention after discharge. Ischaemic stroke patients, younger patients, patients with more comorbid conditions and those discharged home were more likely to receive all three recommended medicine classes. Antibiotics (45 % TIA, 46 % ischaemic stroke), paracetamol (44 % TIA, 47 % ischaemic stroke), antidepressants (26 % TIA, 31 % ischaemic stroke) and laxatives (24 % TIA, 32 % ischaemic stroke) were commonly used after discharge. Increased use of sedatives and reduced use of non-steroidal anti-inflammatories was also observed after discharge. Conclusion Changes to pharmacotherapy after TIA or ischaemic stroke were consistent with treatment for stroke risk factors and common stroke-related complications. Use of secondary stroke prevention medicines may be further improved among TIA patients.

Keywords

Australia Drug utilisation Older people Stroke Transient ischaemic attack 

Notes

Acknowledgments

The authors thank the Australian Government Department of Veterans’ Affairs (DVA) for providing data to conduct this research. This manuscript was reviewed by DVA prior to submission.

Funding

J Sluggett was supported by an Australian Postgraduate Award and University of South Australia scholarship.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

  1. 1.
    Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMedGoogle Scholar
  2. 2.
    MacKay J, Mensah GA, Mendis S, Greenlund K. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004. ISBN: 9789241562768.Google Scholar
  3. 3.
    Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010;9:105–18.CrossRefPubMedGoogle Scholar
  4. 4.
    Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med. 2007;167:2417–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Australian Institute of Health and Welfare. Cardiovascular disease: Australian facts 2011. Cardiovascular disease series. Cat. no. CVD 53. Canberra: AIHW: 2011. ISBN: 978-1-74249-130-1.Google Scholar
  6. 6.
    National Stroke Foundation. Clinical guidelines for stroke management 2010. Melbourne, Australia: 2010. ISBN: 978-0-9805933-3-4.Google Scholar
  7. 7.
    The European stroke organisation. Guidelines for management of ischaemic stroke and transient ischaemic attack; 2008. (cited 26 Sept 2014). http://www.congrex-switzerland.com/fileadmin/files/2013/eso-stroke/pdf/ESO08_Guidelines_Original_english.pdf.
  8. 8.
    Intercollegiate Stroke Working Party. National clinical guideline for stroke. 4th ed. London: Royal College of Physicians; 2012. ISBN: 978-1-86016-492-7.Google Scholar
  9. 9.
    Bath PMW, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ. 2005;330:342.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL. Stroke risk and NSAIDs: an Australian population-based study. Med J Aust. 2011;195:525–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Sluggett JK, Caughey GE, Ward MB, Roughead EE, Gilbert AL. Transient ischaemic attack and ischaemic stroke: constructing episodes of care using hospital claims data. BMC Res Notes. 2013;6:128.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Somerford PJ, Lee AH, Yau KK. Ischemic stroke hospital stay and discharge destination. Ann Epidemiol. 2004;14:773–7.CrossRefPubMedGoogle Scholar
  13. 13.
    National stroke foundation. National stroke audit—acute services clinical audit report 2013. (cited 10 Mar 2014). http://strokefoundation.com.au/site/media/NSF687.ClinicalServicesAudit2013.Final_.pdf. ISBN: 987-0-9872830-7-8.
  14. 14.
    Sweileh WM, Sawalha AF, Zyoud SH, Al-Jabi SW, Abaas MA. Discharge medications among ischemic stroke survivors. J Stroke Cerebrovasc Dis. 2009;18:97–102.CrossRefPubMedGoogle Scholar
  15. 15.
    de Weerd L, Rutgers AWF, Groenier KH, van der Meer K. Health care in patients 1 year post-stroke in general practice: research on utilisation of the Dutch transmural protocol transient ischaemic attack/cerebrovascular accident. Aust J Prim Health. 2012;18:42–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ostwald SK, Wasserman J, Davis S. Medications, comorbidities, and medical complications in stroke survivors: the CAReS study. Rehabil Nurs. 2006;31:10–4.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Australian Government Department of Veterans’ Affairs. Treatment population statistics, quarterly report, Dec 2010. (cited 15 Dec 2013). http://www.dva.gov.au/aboutDVA/Statistics/Documents/TpopDec2010.pdf.
  18. 18.
    World Health Organisation Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses. (cited 21 Dec 2011). http://www.whocc.no/atc_ddd_index/.
  19. 19.
    Australian Government Department of Health. Schedule of Pharmaceutical Benefits. Canberra: Commonwealth of Australia; 2014. (cited 26 Sept 2014). http://www.pbs.gov.au/publication/schedule/2014/09/2014-09-01-general-schedule.pdf.
  20. 20.
    National Centre for Classification in Health. International statistical classification of diseases and related health problems, Tenth Revision, Australian Modification (ICD-10-AM). National Centre for Classification in Health, Faculty of Health Sciences, University of Sydney: Sydney; 2004.Google Scholar
  21. 21.
    Vitry A, Wong SA, Roughead EE, Ramsay E, Barratt J. Validity of medication-based co-morbidity indices in the Australian elderly population. Aust N Z J Public Health. 2009;33:126–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Pratt N, Roughead EE, Salter A, Ryan P. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review. BMC Med Res Methodol. 2012;12:72.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    King MA, Purdie DM, Roberts MS. Matching prescription claims with medication data for nursing home residents: implications for prescriber feedback, drug utilisation studies and selection of prescription claims database. J Clin Epidemiol. 2001;54:202–9.CrossRefPubMedGoogle Scholar
  24. 24.
    McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157:940–3.CrossRefPubMedGoogle Scholar
  25. 25.
    National Stroke Foundation. National stroke audit acute services—clinical audit report 2009. (cited 10 Nov 2011]. http://www.strokefoundation.com.au/index2.php?option=com_docman&task=doc_view&gid=268&Itemid=39.
  26. 26.
    Eissa A, Krass I, Bajorek BV. Use of medications for secondary prevention in stroke patients at hospital discharge in Australia. Int J Clin Pharm. 2014;36:384–93.CrossRefPubMedGoogle Scholar
  27. 27.
    Heeley E, Anderson C, Patel A, Cass A, Peiris D, Weekes A, Chalmers J. Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice. Int J Stroke. 2012;7:649–54.CrossRefPubMedGoogle Scholar
  28. 28.
    National Stroke Foundation. Clinical Guidelines for Acute Stroke Management. Melbourne, Australia: 2007. (cited 26 Sept 2014). http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp109.pdf.
  29. 29.
    Sacco RL, Diener H-C, Yusuf S, Cotton D, Ôunpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–51.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Ovbiagele B, Hills NK, Saver JL, Johnston SC. Secondary-prevention drug prescription in the very elderly after ischemic stroke or TIA. Neurology. 2006;66:313–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Castle J, Mlynash M, Lee K, Finley A, Wolford C, Kemp S, et al. Agreement regarding diagnosis of transient ischemic attack fairly low among stroke-trained neurologists. Stroke. 2010;41:1367–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Palnum KH, Mehnert F, Andersen G, Ingeman A, Krog BR, Bartels PD, et al. Medical prophylaxis following hospitalization for ischemic stroke: age- and sex-related differences and relation to mortality. Cerebrovasc Dis. 2010;30:556–66.CrossRefPubMedGoogle Scholar
  33. 33.
    Raine R, Wong W, Ambler G, Hardoon S, Petersen I, Morris R, et al. Socioeconomic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study. BMJ. 2009;338:b1279.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Westendorp WF, Nederkoorn PJ, Vermeij J-D, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011;11:110.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Balami JS, Chen R-L, Grunwald IQ, Buchan AM. Neurological complications of acute ischaemic stroke. Lancet Neurol. 2011;10:357–71.CrossRefPubMedGoogle Scholar
  36. 36.
    Jönsson A-C, Lindgren I, Hallström B, Norrving B, Lindgren A. Prevalence and intensity of pain after stroke: a population based study focusing on patients’ perspectives. J Neurol Neurosurg Psychiatry. 2006;77:590–5.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    El Husseini N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DWM, et al. Depression and antidepressant use after stroke and transient ischemic attack. Stroke. 2012;43:1609–16.CrossRefPubMedGoogle Scholar
  38. 38.
    Su Y, Zhang X, Zeng J, Pei Z, Cheung RTF, Zhou Q, et al. New-onset constipation at acute stage after first stroke. Stroke. 2009;40:1304–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Elliott RA. Problems with medication use in the elderly: an Australian perspective. J Pharm Pract Res. 2006;36:58–66.CrossRefGoogle Scholar
  40. 40.
    Australian Institute of Health and Welfare. Health care usage and costs. A comparison of veterans and war widows and widowers within the rest of the community. AIHW Cat. no. PHE 42. Canberra: AIHW 2002. ISBN: 978-1-75024-234-6.Google Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Janet K. Sluggett
    • 1
    Email author
  • Gillian E. Caughey
    • 1
  • Michael B. Ward
    • 2
  • Andrew L. Gilbert
    • 1
  1. 1.Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute for Health ResearchUniversity of South AustraliaAdelaideAustralia
  2. 2.School of Pharmacy and Medical SciencesUniversity of South AustraliaAdelaideAustralia

Personalised recommendations